All posts by medical

Aro Biotherapeutics Appoints Leading Cancer Biologist Dr. Martin McMahon and Protein Structure and Design Expert Dr. Ronald Swanson to its Scientific…

Aro Biotherapeutics announced the appointments of Martin McMahon, PhD, and Ronald V. Swanson, PhD, to its Scientific Advisory Board (SAB). Dr. McMahon will provide strategic counsel on the development of novel Centyrin-siRNA therapeutic candidates targeting KRAS and other oncogenic pathways. Dr. Swanson will provide scientific counsel on protein engineering and optimization of novel Centyrin targeting therapeutic candidates.

"We warmly welcome Dr. McMahon, a well-known leader in cancer biology and experimental cancer therapeutics, and Dr. Swanson, an accomplished protein engineer who has been involved in the development of multiple protein therapeutic candidates, to Aros SAB," said Sue Dillon, PhD, Co-Founder and Chief Executive Officer of Aro. "Dr. McMahons expertise will be invaluable to Aro as we progress our Centyrin therapeutic candidates from research into clinical development. In addition, Dr. Swansons biotherapeutics development insights and experience will be extremely helpful for lead optimization. They are both assets to Aro and our SAB."

Dr. McMahons translational cancer research program at the University of Utah focuses on the mechanisms underlying the initiation, progression and maintenance of metastatic melanoma, lung and pancreatic cancers. Prior to his appointments at the Huntsman Cancer Institute in 2015, Dr. McMahon held faculty positions dating back to 1998 at the University of California, San Francisco (UCSF) Helen Dillar Family Comprehensive Cancer Center where he served as a Distinguished Professor of Cancer Biology, Co-Leader of the Experimental Therapeutics Program and Director for Professional Education. Prior to UCSF, Dr. McMahon headed an independent research group at DNAX Research Institute in Palo Alto (now Merck Research Laboratories). He currently serves as the Cumming-Presidential Chair of Cancer Biology in the Department of Dermatology, Senior Director for Preclinical Translation and Co-Leader of the Experimental Therapeutics Program in the Huntsman Cancer Institute. Dr. McMahon graduated with a B.Sc. (Hons) in Biochemistry from Glasgow University in 1981 and a doctorate from Kings College, University of London in 1985. He completed a postdoctoral fellowship under the mentorship of J. Michael Bishop at UCSF investigating the mechanisms of action of oncoprotein kinases such as SRC, ERBB and RAF.

Dr. McMahon commented, "It is an honor to work with the Aro team to help advance transformational new therapeutics using the Centyrin technology to deliver novel cancer therapeutics directly to cancer cells. This technology has the promise to increase therapeutic anti-cancer efficacy and reduce potential toxicity to patients."

Dr. Swanson is Chief Scientific Officer at Tyra Biosciences, a company focused on targeting acquired resistance in oncology. Prior to Tyra, Dr. Swanson managed the Johnson & Johnson (J&J) Lead Discovery & Optimization group based in San Diego focused on engineering of antibodies, peptides and protein therapeutics. He was Senior Director of New Platforms and Technologies before retiring from J&J last year to return to a biotech startup environment. He began his career as Director of Genomics and Protein Expression at then biotech startup Diversa working on enzyme discovery and directed evolution. He later joined the newly founded Syrrx as Director of Molecular Biology focused on high-throughput protein structure determination and structure-based drug design. He was co-founder and CSO at ActiveSight, a pioneering structural biology contract research organization. Dr. Swanson graduated from University of California, San Diego with a BA in Biochemistry and Cell Biology in 1985 and from University of California, Berkeley in 1991 with a PhD in Molecular Biology under the guidance of Alex Glazer studying post-translational modifications of proteins. His postdoctoral fellowship was done with Mel Simon at Caltech working on protein-protein interactions in signal transduction and thermostable proteins.

Dr. Swanson commented, "It is great to be involved with the Aro team developing a novel platform for truly differentiated new therapeutics. The ability to access intracellular targets with the Centyrin technology allows for engineering highly specific and stable therapeutics that will profoundly impact disease treatment."

Story continues

Building a Pipeline of Life Changing Therapies

Centyrins are small, structurally simple, ultra-stable, highly soluble proteins. These characteristics enable the discovery of medicines with new mechanisms of action for cancer and other devastating diseases. Aros lead program is a bi-specific Centyrin-siRNA conjugate in late-stage lead optimization for KRAS mutant cancers. This first-of-its-kind combination is designed to address unmet medical needs by targeting drug payloads in high concentration to the site of disease, while lowering the toxicity to non-target organs. The company holds an exclusive worldwide license for research, development, manufacturing and commercialization of Centyrin protein therapeutics.

About Aro Biotherapeutics

Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins. Centyrins are ideal targeting moieties that enable cell specific uptake of biological payloads. The company is developing a wholly-owned pipeline of Centyrin conjugates for oncology and immunology. For more information, visit http://www.arobiotx.com.

CENTYRIN is a trademark of Johnson & Johnson.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005085/en/

Contacts

Media Contact Mike BeyerSam Brown Inc.mikebeyer@sambrown.com 312-961-2502

Read more:
Aro Biotherapeutics Appoints Leading Cancer Biologist Dr. Martin McMahon and Protein Structure and Design Expert Dr. Ronald Swanson to its Scientific...

Diverse Biotech selected to present at upcoming BIO Meeting and announces new Gene Expression Paper Publication – WFMZ Allentown

DOYLESTOWN, Pa., Feb. 10, 2020 /PRNewswire/ -- Diverse Biotech, Inc. http://www.diversebiotech.com has announced it has been selected to present at the upcoming BIO CEO & Investor Conference in New York on February 11th. https://www.bio.org/events/bio-ceo-investor-conference/sessions/659395

In addition, Diverse Biotech has announced that a paper regarding cannabinoid-related gene expression was accepted by the Journal of Applied Cell Biology.The paper should be published in the next 3-4 weeks.

"We are truly excited to continue to discuss our ground-breaking technology.In addition, the gene expression paper is tremendous because it highlights that a variety of cell lines including glioblastoma, pancreatic cancer, melanoma, actinic keratosis, squamous cell carcinoma, and normal skin all express genes that suggest they will be responsive to exogenous cannabinoid treatment," saidStella Vnook, Diverse Biotech's Chief Executive Officer.

About Diverse Biotech

Diverse Biotech is a US-based biopharmaceutical company, focused on medical discoveries and the development of new molecules for the treatment of Cancer and other debilitating diseases.Our focus is on discovering and developing novel therapeutics utilizing cannabidiol (CBD) as a core component and combining it through highly advanced chemistry with other molecules to develop new chemical entities that are theoretically more efficacious and less toxic. Our initial focus is on hard-to-treat oncologic disorders including basal cell carcinoma and other Dermatology related cancers, Pancreatic cancer and Glioblastoma, where targeted therapies have proven largely unsuccessful thus far and there is significant unmet need.

Further information about Diverse Biotech can be found at http://www.diversebiotech.com.

Contacts:Brian LongstreetChief Business OfficerDiverse Biotech, Inc+1-908-917-5699blongstreet@diversebiotech.com

Link:
Diverse Biotech selected to present at upcoming BIO Meeting and announces new Gene Expression Paper Publication - WFMZ Allentown

Synthetic biology is shaking up these 5 industries-Some of them might surprise you – SynBioBeta

Ask any researcher for a definition of synthetic biology, and youll get a different answer. Synthetic biology is an incredibly diverse field with applications that span the biotechnology gamut. But what makes the field difficult to define also makes synthetic biology a wellspring of opportunities for jobseekers. In this post, we highlight a few of the growing fields where burgeoning synthetic biologists can expect to find job opportunities.

The oldest application of biotechnology is arguably biomanufacturing of insulin. Scientists discovered how to co-opt yeast and bacteria into producing human medicines decades ago. But while producing insulin only requires a single gene, there are many important medicines such as taxol (an anti-cancer drug) that require entire pathways. Thats where synthetic biology comes in.

There are a multitude of companies using synthetic biology to engineer pathways that enable microorganisms to produce medically relevant drugs. Famously, Amyris engineered yeast to produce the antimalarial drug Artemenisin. Synthetic biology can also improve in-vitro drug manufacturing. For instance, Codexis uses synthetic biology to develop more efficient enzymes for synthesis of small molecule drugs.

Beyond biomanufacturing of drugs, there are many other ways to apply synthetic biology to biopharma research. For instance, there are several companies engineering microbes not only to produce medicines, but to deliver them in vivo. These so-called engineered probiotics could potentially be tuned to produce drugs in response to a particular stimulus or only in certain parts of the body.

As science reveals more about the microorganisms living in and on us, companies are developing microbiome-based therapeutics to target a litany of diseases. Skin microbiome company Azitra shares their approach to effectively developing, testing, and bringing microbiome-based therapeutics to the clinic. Image source: Azitra

Companies are also engineering human cells for therapeutic purposes. This is the basis for CAR-T cell therapy, a promising new approach to cancer treatment. Beyond single cells, some companies are focused on developing synthetic tissues and whole synthetic organoids for research or therapeutic purposes.

Companies to watch:

A major goal of the synthetic biology industry is to develop alternative, biology-based methods for industries that typically use petroleum-based products as inputs and produce carbon emissions as outputs.

There are many companies working to produce biofuels or bioplastics. For instance, Synthetic Genomics is engineering algae as biofactories for renewable fuel, and Global Bioenergies is developing processes to ferment plant waste into petrochemical precursors.

Others are working to fix carbon more directly by attempting to optimize natural carbon-fixers (plants and cyanobacteria). Long-term carbon storage is also a challenge, and its one some synthetic biologists think bacteria can solve by converting carbon dioxide into a liquid state.

Carbon emissions dont only come from burning fuel, however. There are also biological and environmental sources of greenhouse gas. LanzaTech sees these sources as a useful starting point for making high-value chemicals. Its carbon recycling technology platform captures and converts so-called biogas from agricultural and municipal waste, then converts it to biofuels and other products.

Together, these efforts comprise what could make up a circular economy in which biology is both the source and the byproduct of many of the products that we depend on instead of petrochemicals.

Companies to watch:

Carbo Culture is pioneering a product to tackle both agricultural air pollution and soil degradation. Biochar plays an active role in a balanced carbon cycle.

We dont often think about the science behind our clothing, but if you look at the tags of anything youre wearing right now, youll probably be reminded that fashion is fed by a complex mashup of materials. Clothes are a mixture of plant-based materials (like cotton), petroleum-based materials (like nylon and spandex), and animal-based materials (like leather and silk). The fibers that make up our garments are also almost always bleached or dyed and chemically treated. With all of this complexity, fashion can have a bit of a nasty environmental footprint.

There are several companies using synthetic biology to come up with greener alternatives for fashion must-haves. For instance, Tinctorium, PILI, and Colorifix are finding a way to dye blue jeans without producing hazardous waste. In addition, Mango Materials is using bacteria to turn methane into bioplastics for clothing and other goods that will degrade naturally if they end up in our oceans as so much waste does.

Sourcing colors from a range of natural pigments, Colorifix engineers microorganisms to convert agricultural by-products into dyes. When the microorganisms burst they fix the colour to the fabric, thus reducing the need for massive amounts of water, according to BBC Earth. Photo by Marianna Limas

Even fashion icons are taking notice. High fashion designer Stella McCartney is bringing synthetic biology to the runway by partnering with Bolt Threads, a synthetic biology company endeavoring to make synthetic silk and faux leather from mushrooms. Bolt is not alone; synthetic silk companies are popping up all over the world, including AMSilk in Germany and Spiber in Japan, and theres a company in New York called Ecovative Design thats using mushrooms to create all sorts of materials for clothing, footwear, and beyond.

Companies to watch:

Your clothes may not be the only thing youre wearing that will soon be shaped by synthetic biology. There are also synthetic biology companies targeting makeup, skin creams, cologne, and perfume.

Traditional ingredients for cosmetics are often animal-based, raising purity and animal rights concerns. For example, collagen is a popular ingredient in high-end anti-wrinkle creams, because its responsible for skin elasticity. But collagen is sourced from animals, meaning its not vegan-friendly, and it can elicit purity and allergy issues. Geltor is using synthetic biology to produce animal-free collagen substitutes. Biossance, an Amyris spinoff, has also used synthetic biology to create an animal-free cosmetic additive, squalane, which was traditionally harvested from shark livers.

HumaColl21 is just one example of how a biodesigned future leads to better products for improving peoples lives. Image: Geltor

In addition to taking an environmental toll, ingredients for cosmetics and, especially fragrances, can be incredibly expensive. The essence of grapefruit is captured by a flavor compound called nootkatone. At about $200 per gram, true, pure nootkatone is limited to higher end colognes. A synthetic biology company called Evolva wants to change that by producing nootkatone and other fragrance compounds via fermentation. Conagen is also using microbial fermentation to produce high-value flavors and fragrances such as vanillin, while Motif Foodworks (a spinout of synthetic biology unicorn Ginkgo Bioworks) is also brewing up new sources for fragrances such as the essence of a rose.

Companies to watch:

This category deserves several posts all its own. Synthetic biology companies are reimagining the food space in several ways from revolutionizing agriculture to tackling food waste to coming up with more environmentally-friendly sources of food additives.

Starting with the plants in the ground, companies like Pivot Bio and Joyn Bio are engineering soil bacteria to end our dependence on synthetic fertilizers.

Other synthetic biology companies are focused on what happens to food after its harvested. For example, Conagen is engineering strains of microorganisms and novel enzymes to synthesize all sorts of food-additives from food colorings, to sweeteners, to meat tenderizers, to preservatives.

But companies arent just focused on solid ground. AquaBounty, for example, is combining advances in aquaculture with modern genetics to create the worlds most sustainable salmon, while Air Protein is using bacterial fermentation to make protein from the elements comprising the air we breathe.

Several companies, such as Memphis Meats and Meatable, are allowing us to have our animals and eat them too, using synthetic biology to create real meat without harming animals or the planet.

Companies to watch:

The limited run of Perfect Day ice cream is already sold out, but it showed big food producers how microflora can be used to produce animal-free ingredients for milk, dairy, cheese, and ice cream. Image: Perfect Day Foods.

The five synthetic biology focus areas highlighted here are far from an exhaustive list. And for every company working on a specific application, there are others like Evonetix, Twist Bioscience, Inscripta, Ginkgo Bioworks, and Benchling that are building the DNA synthesis, editing, organism engineering, and data tools that the entire synthetic biology industry depends on.

While synthetic biologists offer varying definitions of the field, most will agree that an overarching goal of the industry is to shift our reliance away from chemistry and fossil fuels and towards biology. Its a lofty goal, but with so many diverse companies working to support it, synthetic biology will have a major role in shaping the future of technology across industries.

Original post:
Synthetic biology is shaking up these 5 industries-Some of them might surprise you - SynBioBeta

ACSM Tackles Myth on Genetics and Heart Disease as Part of American Heart Month – Newswise

MEDIA CONTACT

Available for logged-in reporters only

Feature

MEDICINE

Newswise (Indianapolis, IN) Nearly half of all U.S. adults have some type of cardiovascular disease. Its a heartbreaking statistic literally and figuratively. People often believe their risk for heart disease cannot be reduced if they have a genetic predisposition. In honor of American Heart Month, the American College of Sports Medicine (ACSM) and ACSM Fellow Beth A. Taylor, Ph.D., have teamed up to shatter this heart myth.

The truth about the heritability (or genetic component) of heart disease is a glass far more full than empty, as long as we look at it accurately, says Dr. Taylor, associate professor of kinesiology at the University of Connecticut and the director of exercise physiology research at Hartford Hospital.

Genetics do play a significant role in increasing heart disease risk. Research shows that individuals at high genetic risk have a 91% higher chance of experiencing a cardiac event, yet that risk can be cut nearly in half by adopting healthy lifestyles.

We may have genes that predispose us to cardiovascular disease, but when, how and to what extent those genes express themselves is highly influenced by lifestyle, says Dr. Taylor. Being more physically active, aiming for a healthy weight, eating a heart healthy diet and avoiding smoking can improve heart health and reduce the risk of coronary events by 46% for high genetic risk individuals.

The outlook looks even better when considering being healthy across the lifespan rather than at a single age. The Framingham Heart Study, a project of Boston University and the National Heart, Lung and Blood Institute (NHLBI), has sought to identify common factors contributing to cardiovascular disease (CVD) by following CVD development in three generations of participants.

Dr. Taylor adds, When those three generations of the Framingham Heart Study were reviewed, investigators concluded that the heritability of ideal cardiovascular health was only 13-18%, with health behaviors and lifestyle factors being much more influential.

She says other studies have found that adhering to just four out of five of healthy lifestyle factors (e.g., avoiding smoking and excessive alcohol intake, performing 30 or more minutes a day of moderate-to-vigorous physical activity, eating a heart healthy diet) increased the likelihood of living free of cardiovascular disease, as well as cancer and Type 2 diabetes, by more than 10 years in women and seven years in men.

For Dr. Taylor, the take-home message is simple. You cant completely cure a broken heart; however, you can make it better or worse based on your lifestyle. The choice is yours!

Find more heart health resources from ACSM at https://www.acsm.org/read-research/trending-topics-resource-pages/heart-health-resources.

# # #

About the American College of Sports Medicine

The American College of Sports Medicine is the largest sports medicine and exercise science organization in the world. More than 50,000 international, national and regional members and certified professionals are dedicated to advancing and integrating scientific research to provide educational and practical applications of exercise science and sports medicine. More details at acsm.org.

Continued here:
ACSM Tackles Myth on Genetics and Heart Disease as Part of American Heart Month - Newswise

BRIEF-Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response – Reuters

Feb 11 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS AND ASTELLAS ANNOUNCE UPDATED RESULTS FROM PHASE 1B/2 TRIAL OF PADCEV (ENFORTUMAB VEDOTIN-EJFV) IN COMBINATION WITH IMMUNE THERAPY PEMBROLIZUMAB AS INVESTIGATIONAL FIRST-LINE TREATMENT FOR ADVANCED BLADDER CANCER

* SEATTLE GENETICS - AFTER MEDIAN FOLLOW-UP OF 11.5 MONTHS, 73% OF PATIENTS HAD CONFIRMED TUMOR RESPONSE WITH MAJORITY OF RESPONSES STILL ONGOING

* SEATTLE GENETICS INC - NO NEW SAFETY SIGNALS OBSERVED FOR COMBINATION Source text for Eikon: Further company coverage:

More:
BRIEF-Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response - Reuters

Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News

Back a little over 5 years ago, I reported on a major disaster for Exelixis $EXEL when cabozantinib flopped in a comparison with prednisone in treating castration-resistant prostate cancer. Caught between a rock and a hard place, the company immediately whacked 70% of its work force, as new CEO Michael Morrissey steered away from the rocks with what was left of the crew.

Morrissey and the survivors took a conservative course, hanging on to get an OK for the TKI, which ultimately proved a fairly effective market maker as Cabometyx, with more than $1 billion in total revenue over a 4-quarter stretch. And at JP Morgan a few weeks ago Morrissey threw his customary caution to the wind, painting a rosy picture of the future, with a potential to make the company into a $4 billion earner by 2025, with 3 upcoming pivotal readouts.

Unlock this story instantly and join 71,900+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

See original here:
Merck-allied Seattle Genetics' positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line - Endpoints News

Mexico: Feed prices allow for production growth, genetic focus – FeedNavigator.com

The US Department of Agriculture (USDA) released new information regarding feed use and livestock production in Mexico in a report from the Foreign Agricultural Service (FAS) on Friday.

Increasing livestock production in Mexico has been supported by the movement toward vertical integration in production and improved biosecurity, the FAS reported. Stable feed prices and better zoo-sanitary conditions suggest that the expansion will continue.

Feed price consistency has allowed livestock breeders to seek better genetics, the agency said.

Feed prices did slightly fluctuate in the last two quarters of 2019, but industry expects overall grain and feed price stability to prevail through 2020, the agency said. The stability in feed prices as well as steady domestic livestock prices allow producers to focus their operations more on breeding than slaughtering.

In marketing year (MY) 2020, beef production is expected to reach 2.1m metric tons (MT) and consumption is expected to reach 1.9m MT, the FAS said. Industry growth from 2015 through 2019 averaged about 2% annually, despite changes in prices for feed and grains.

The Mexican beef industry has kept a steady pace of investments, adaption of new and improved production practices, as well as improved technology to stimulate the beef production sector, the agency said.

Swine production in MY 2020 is anticipated to be a 20.3m head based on increasing consumer demand and supported by vertical integration of producers, the agency said. Pork production is forecast to reach 1.47m MT.

According to industry studies, pork consumption has increased as a share of domestic consumption from 28% to close to 32%, with poultry retaining the biggest share at over 60%, the agency said.

During the 2018-19 export cycle, Mexicos exports of cattle to the US reached 1.313m animals an increase of 17.6% from the previous year, the FAS said. Trade has been valued at more than $760m.

Trade is expected to continue expanding, if more slowly, during MY 2020, the agency said.

A pilot program has been established to regulate trade and improve zoo-sanitary status in live cattle coming in from Guatemala, the agency said. The agreement emphasizes that cattle to be exported from Guatemala will come from ranches certified by the Ministry of Agriculture of Guatemala (MAGA) as free of bovine tuberculosis and brucellosis, which will be tagged with the Central American Electronic Earring and utilizes radio reference technology.

Personnel from MAGA and the International Regional Agency for Agricultural Health (OIRSA) will verify the fulfillment of a 21-day quarantine of cattle at the ranch of origin or in the feedlots constituted for it, FAS said. Currently, 70 ranches in Guatemala have been certified, and the program is set to run through November 2024.

Beef imports in MY 2020 are expected to increase to 212,000 MT, the agency said. The United States remain the main beef provider to Mexico with 86% market share, followed by Canada with 7.5%, and Nicaragua with 4.7%.

Exports of beef in MY 2020 are forecast to increase by 10% and reach 347,000 MT, the FAS said. Expanding the use of feedlot-based production is one factor supporting the increased exports.

Japan is consolidated as the second most important export market for Mexican beef, comprising 7% of Mexicos beef exports, followed by Hong Kong with 4%, the agency said. For many years, South Korea was the third most important Mexican beef export destination, but now holds the fourth position with 2% of market share.

On the swine side, the forecast for MY 2020 calls for live hog imports of 41,000 head and pork imports of 1m MT, the agency said. Mexico is dependent on imports to meet domestic demand, but imports have been slow based on the countrys economy.

In MY 2020, imports will rise compared to their low in 2019, as pork consumption continues its positive trend and growing exports to China compete with domestic consumption, the FAS reported.Mexico will resume imports from the United States in order to satisfy the domestic demand.

Pork exports are predicted to reach a record 250,000 MT as Mexico focuses on supplying Asian markets, the agency said.

Mexican pork exports have grown considerably through 2019, especially to Japan, the agency said.The trend will continue as the industry is expecting an important growth of exports for 2020, especially to China.

Here is the original post:
Mexico: Feed prices allow for production growth, genetic focus - FeedNavigator.com

Government considers storage limit extension for frozen eggs, sperm and embryos – The Argus

The limit on how long frozen eggs, sperm and embryos can be stored may be extended amid concerns women are being disproportionately affected, the Government has announced.

Currently, the storage period is a maximum of 10 years, after which families must decide whether to undergo fertility treatment or have their eggs, sperm and embryos destroyed.

The Department of Health and Social Care is asking people whether they feel this should be changed amid fears that the 10 year limit disproportionately affects women who want to freeze their eggs.

The number of women freezing their eggs has soared by 257% since 2012, with 1,462 egg freezing cycles in 2017 compared to 410 in 2012, while freezing technologies have become more advanced.

Only those stored for medical reasons, such as cancer treatment, and premature infertility can be preserved for longer up to 55 years in total.

Both men and women may freeze their sperm and/or eggs for non-medical reasons, such as wanting to have children in future but not having a partner.

The Government is launching a public consultation into whether the limit should be changed.

Minister for Care Caroline Dinenage said: Every person should be given the best possible opportunity to start a family, which is why it is so important that our laws reflect the latest in technological advancements.

Although this could affect any one of us, I am particularly concerned by the impact of the current law on womens reproductive choices.

A time limit can often mean women are faced with the heart-breaking decision to destroy their frozen eggs, or feel pressured to have a child before they are ready.

As the number of people seeking this storage rises, we want to hear from the public about whether the law is fair and proportionate, and ensure everyone is empowered to choose when they become parents.

A woman has a better chance of a healthy pregnancy if she freezes her eggs in her 20s when her fertility is at its peak.

However, the current 10-year limit would then expire in her 30s, which may be too early for some women to start a family.

The most common age for women to freeze their eggs is currently 38.

The Government will also consider issues of safety and quality, and additional demand for storage facilities, should the limit be extended.

Sally Cheshire, chairwoman of the Human Fertilisation and Embryology Authority, said: As the fertility regulator we have heard the voices of patients and clinicians calling for a review and extension of the current time limit for egg, embryo and sperm storage.

While any change to the 10-year storage limit would be a matter for Parliament as it requires a change in law, we believe the time is right to consider what a more appropriate storage limit could be that recognises both changes in science and in the way women are considering their fertility.

Go here to see the original:
Government considers storage limit extension for frozen eggs, sperm and embryos - The Argus

INmune Bio, Inc. Awarded $500000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS – BioSpace

Grant will fund proof-of-concept studies for XPro1595 therapy

LA JOLLA, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- INmuneBio, Inc. (NASDAQ: INMB), an immunology company developing treatments that reprogram the patients innate immune system to fight disease, today announced that it has been awarded a $500,000 grant from The ALS Association. The grant will fund proof-of-concept studies for XPro1595, a novel therapy targeting innate immune dysfunction and chronic inflammation as a cause of Amyotrophic lateral sclerosis (ALS). The endowment was awarded through the Associations The Lawrence and Isabel Barnett Drug Development Program and will be allocated over two years.

We are honored to receive this grant from The ALS Association, the pre-eminent organization supporting novel treatments for ALS, said R.J. Tesi, M.D., Chief Executive Officer of INmune Bio. As an immunology company, we focus on the role that innate immune dysfunction and neuroinflammation play in the progression of neurodegenerative diseases such as ALS. This award supports our approach and moves the companys ALS program closer to the clinic.

While our knowledge of ALS has increased dramatically in the past few years, there are currently no disease modifying therapies, said CJ Barnum, Ph.D., Director of Neuroscience for INmune Bio. The innate immune system plays a central role in the development and progression of ALS. We believe precision targeting of the innate immune system by targetinginflammationwith XPro1595may be an effective treatment strategy inalleviating ALS. This award allows INmune Bio to take the first step to determine whether XPro1595 has therapeutic potential for ALS patients.

We believe INmune is on a path to unlocking some of the mystery around the immune system and how it responds to the kinds of inflammation that we know plays a role in ALS progression, said Kuldip Dave, Ph.D, vice president of research at The ALS Association. This grant will greatly accelerate proof of concept and advance our knowledge of immune dysfunction and neuroinflammation in people living with ALS.

About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patients innate immune systems response to their disease - immune priming platform and DN-TNF platform. The immune priming platform is a Natural Killer (NK) cell therapeutic that primes the patients NK cells to attack residual disease the cause of cancer relapse. The DN-TNF platform includes programs in cancer, neurodegenerative disease and NASH. INB03 modifies the tumor microenvironment which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors and trastuzumab. XPro1595 targets microglial activation, nerve cell death and synaptic dysfunction associated with neurodegenerative disease. LivNate modifies metabolic and immunologic pathology that contributes to the development and progression of NASH. To learn more, please visit http://www.inmunebio.com.

About The ALS AssociationThe ALS Association is the largest private funder of ALS research in the world. The Association funds global research collaborations, provides assistance for people with ALS and their families through its nationwide network of chapters and certified clinical care centers, and advocates for better public policies for people with ALS. The ALS Association builds hope and enhances quality of life while urgently searching for new treatments and a cure. For more information about The ALS Association, visit our website at http://www.alsa.org. For more information about The Lawrence and Isabel Barnett Drug Development Program, please visit: http://www.alsa.org/research/our-approach/call-for-abstracts/barnett-drug-development-request-for-proposals-081619.html

Forward-Looking Statements

There is no guarantee that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INBO3, LivNate, INKmune and XPro1595 are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Companys filings with the Securities and Exchange Commission, including the Companys Annual Report on Form 10-K for the year ended December 31, 2018, the Companys Quarterly Reports on Form 10-Q and the Companys Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contact: David Moss, CFO(858) 964-3720DMoss@INmuneBio.com

The ALS Association Contact:Brian Frederick,Ph.D. Executive Vice President, Communications(202) 464-8612bfrederick@alsa-national.org

Media Contact:David Schull(212) 845-4271David.Schull@russopartnersllc.com

Investor Contact:James CarbonaraHayden IR(646)-755-7412james@haydenir.com

More:
INmune Bio, Inc. Awarded $500000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS - BioSpace

‘We’re responding to this threat’: University of Alberta works to help stop novel coronavirus – Edmonton Journal

The University of Albertas Li Ka Shing Institute of Virology says a drug once used in an Ebola outbreak could fight the novel coronavirus.

Remdesivir will be tested against the virus, known as 2019-nCoV, at the institute in Edmonton. Although there are regulatory hurdles related to getting samples of the coronavirus into the country, lab work has already begun, said Dr. Lorne Tyrrell, founding director of the Li Ka Shing Institute of Virology.

The prospects for developing an antivirus that can be used in patients is very good, and it may happen in the next few weeks and be readily available some compounds that are already on the market for their viruses that might work (against) this virus, said Tyrrell.

The institute is aiming to raise up to half a million dollars in funding, including rapid response grants from the Canadian Institute of Health Research, to go towards work on the novel coronavirus, Tyrrell said.

No one at the institute specializes in coronavirus at the moment. That is going to change very quickly, said Tom Hobman, professor of medical microbiology and immunology at the university, who noted that experts on coronaviruses have been recruited.

Since it can take years to get a brand new drug to market, researchers at the institute hope to find a drug thats already been developed to fight the virus.

Remdesivir, one of the drugs they will test, was used in the emergency treatment of patients with Ebola virus infection in the Democratic Republic of the Congo. The drug has shown activity in animal models against the viral pathogens MERS and SARS, which are coronaviruses that are structurally similar to the novel coronavirus, and has been used on a small number of patients.

Since the outbreak of the new coronavirus, it was just logical to ask whether this drug will work against the new coronavirus. The good thing was that its been tested, with tons of pre-clinical data, as well as in very difficult clinical settings, said Matthias Gtte, chair of the department of medical microbiology and immunology.

We are interested, always, not in the entire virus, but in the little machines the enzymes that help the virus to propagate. As soon as you shut down the machine, you shut down the virus, and you have a drug, said Gtte. Now, the goal is to see if the mechanism works the same way against the novel coronavirus.

If youre trying to respond very quickly to an outbreak, you dont really have the luxury of time to develop something completely new, said Dave Evans, professor of medical microbiology and immunology.

The challenge with all drug development is making sure it works and is safe, so its a common approach to test drugs that are known to be safe on new viruses, said Evans.

Viruses change, and new viruses are always emerging, said Tyrrell.

Public health efforts to contain the novel coronavirus have been more challenging than in other outbreaks, including SARS, but the mortality rate is so far much lower, he said. There have been at least 40,000 confirmed cases of the novel coronavirus worldwide, and 910 deaths, according to The World Health Organizations latest numbers.

(The institute) has been designed to look after major outbreaks in the world like this, and I just want you to know that were responding to this threat, said Tyrrell.

lijohnson@postmedia.com

twitter.com/reportrix

Go here to see the original:
'We're responding to this threat': University of Alberta works to help stop novel coronavirus - Edmonton Journal